Early research (Phase 1)Ended earlyNCT01611675What this trial is testingLeflunomide+Vemurafenib in V600 Mutant Met. MelanomaWho this might be right forMelanoma Massachusetts General Hospital 3
Early research (Phase 1)WithdrawnNCT02915666What this trial is testingA Clinical Trial of Patients With MelanomaWho this might be right forMelanoma University of Texas Southwestern Medical Center
Testing effectiveness (Phase 2)Study completedNCT04059224What this trial is testingTraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type MelanomaWho this might be right forStage IV MelanomaStage III Melanoma Universitair Ziekenhuis Brussel 45
Large-scale testing (Phase 3)Study completedNCT01689519What this trial is testingA Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic MelanomaWho this might be right forMalignant Melanoma Hoffmann-La Roche 495
Large-scale testing (Phase 3)Ended earlyNCT02967692What this trial is testingThe Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced MelanomaWho this might be right forMelanoma Novartis Pharmaceuticals 568
Testing effectiveness (Phase 2)Active Not RecruitingNCT01989585What this trial is testingTesting the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant MelanomaWho this might be right forClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Malignant Solid Neoplasm+2 more National Cancer Institute (NCI) 75
Large-scale testing (Phase 3)Study completedNCT01584648What this trial is testingA Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant MelanomaWho this might be right forMelanoma Novartis Pharmaceuticals 423
Early research (Phase 1)Active Not RecruitingNCT05538130What this trial is testingLearn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsWho this might be right forMelanomaGliomaThyroid Cancer+10 more Pfizer 148
Testing effectiveness (Phase 2)Ended earlyNCT04655157What this trial is testingSafety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose IpilimumaWho this might be right forMelanoma Jason J. Luke, MD 2
Early research (Phase 1)Study completedNCT01436656What this trial is testingA Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant MelanomaWho this might be right forMelanoma and Metastatic Colorectal Cancer Pfizer 107
Early research (Phase 1)Looking for participantsNCT04903119What this trial is testingNilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic MelanomaWho this might be right forMetastatic MelanomaBRAF Gene Mutation Rina Plattner 30
Testing effectiveness (Phase 2)Study completedNCT02902029What this trial is testingEvaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaWho this might be right forMalignant Melanoma University Hospital, Essen 186
Large-scale testing (Phase 3)Study completedNCT01245062What this trial is testingGSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive MelanomaWho this might be right forMelanoma GlaxoSmithKline 322
Testing effectiveness (Phase 2)Study completedNCT01512251What this trial is testingBKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced MelanomaWho this might be right forBRAF Mutant Metastatic Melanoma University of California, San Francisco 8
Early research (Phase 1)Study completedNCT03864042What this trial is testingPharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid TumorsWho this might be right forAdvanced Solid TumorsMetastatic Melanoma Pfizer 56
Large-scale testing (Phase 3)Study completedNCT01909453What this trial is testingStudy Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant MelanomaWho this might be right forMelanoma Pfizer 921
Testing effectiveness (Phase 2)WithdrawnNCT03972046What this trial is testingNeoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant MelanomaWho this might be right forMelanoma (Skin)Melanoma Stage IIIb-IVM1aMetastasis Skin+2 more TriHealth Inc.
Testing effectiveness (Phase 2)Study completedNCT01266967What this trial is testingGSK2118436 in BRAF Mutant Metastatic Melanoma to the BrainWho this might be right forMelanoma and Brain Metastases GlaxoSmithKline 172
Early research (Phase 1)WithdrawnNCT04759846What this trial is testingHepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF MelanomaWho this might be right forBRAF V600 MutationUnresectable MelanomaMetastatic Melanoma+1 more Pierre Fabre Medicament
Testing effectiveness (Phase 2)Study completedNCT01320085What this trial is testingA Phase II Study of Single Agent MEK162 in Patients With Advanced MelanomaWho this might be right forBRAF or NRAS Mutant Metastatic Melanoma Pfizer 183